[go: up one dir, main page]

HUP0200495A3 - Method of treating eating disorders - Google Patents

Method of treating eating disorders

Info

Publication number
HUP0200495A3
HUP0200495A3 HU0200495A HUP0200495A HUP0200495A3 HU P0200495 A3 HUP0200495 A3 HU P0200495A3 HU 0200495 A HU0200495 A HU 0200495A HU P0200495 A HUP0200495 A HU P0200495A HU P0200495 A3 HUP0200495 A3 HU P0200495A3
Authority
HU
Hungary
Prior art keywords
eating disorders
treating eating
treating
disorders
eating
Prior art date
Application number
HU0200495A
Other languages
English (en)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22418412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0200495(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of HUP0200495A2 publication Critical patent/HUP0200495A2/hu
Publication of HUP0200495A3 publication Critical patent/HUP0200495A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU0200495A 1999-03-19 2000-03-17 Method of treating eating disorders HUP0200495A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12515099P 1999-03-19 1999-03-19

Publications (2)

Publication Number Publication Date
HUP0200495A2 HUP0200495A2 (en) 2002-08-28
HUP0200495A3 true HUP0200495A3 (en) 2004-09-28

Family

ID=22418412

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200495A HUP0200495A3 (en) 1999-03-19 2000-03-17 Method of treating eating disorders

Country Status (23)

Country Link
US (1) US6365633B1 (hu)
EP (1) EP1178789B1 (hu)
JP (1) JP2003519087A (hu)
KR (1) KR100432825B1 (hu)
CN (1) CN1188120C (hu)
AT (1) ATE401066T1 (hu)
AU (1) AU773188C (hu)
BR (1) BR0009026A (hu)
CA (1) CA2367666C (hu)
CZ (1) CZ20013278A3 (hu)
DE (1) DE60039508D1 (hu)
ES (1) ES2307501T3 (hu)
HK (1) HK1045455B (hu)
HU (1) HUP0200495A3 (hu)
IL (1) IL145240A (hu)
MX (1) MXPA01009404A (hu)
NO (1) NO20014479L (hu)
NZ (1) NZ514011A (hu)
PL (1) PL351963A1 (hu)
SK (1) SK12992001A3 (hu)
TR (1) TR200102646T2 (hu)
WO (1) WO2000054765A1 (hu)
ZA (1) ZA200107533B (hu)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7572783B2 (en) * 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006253312B2 (en) 2005-05-30 2011-08-18 Msd K.K. Novel piperidine derivative
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
US20090203738A1 (en) * 2005-09-22 2009-08-13 Eisai R&D Management Co., Ltd. Pharmaceutical Composition for Treating Bulimia and Depression Arising from Bulimia
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
US8163770B2 (en) 2005-10-27 2012-04-24 Msd. K. K. Benzoxathiin derivative
US8158791B2 (en) 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
MX2009007720A (es) 2007-01-16 2013-03-22 Ipintl Llc Nueva composicion para el tratamiento del sindrome metabolico.
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2219664A1 (en) * 2007-11-14 2010-08-25 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
PE20140859A1 (es) 2011-02-25 2014-07-25 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN107207483B (zh) 2014-08-29 2020-10-30 Tes制药有限责任公司 α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
TW202033516A (zh) 2018-11-20 2020-09-16 義大利商Ｔｅｓ製藥（股份）責任有限公司 α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
AU744261B2 (en) * 1997-04-24 2002-02-21 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating eating disorders
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
PL349002A1 (en) * 1999-01-20 2002-06-17 Knoll Pharmaceutical Co Method to aid smoking cessation
ES2238999T3 (es) * 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.

Also Published As

Publication number Publication date
IL145240A0 (en) 2002-06-30
JP2003519087A (ja) 2003-06-17
EP1178789A4 (en) 2004-02-18
CA2367666C (en) 2008-11-25
CN1188120C (zh) 2005-02-09
DE60039508D1 (de) 2008-08-28
ATE401066T1 (de) 2008-08-15
EP1178789A1 (en) 2002-02-13
CZ20013278A3 (cs) 2002-07-17
WO2000054765A1 (en) 2000-09-21
NO20014479D0 (no) 2001-09-14
WO2000054765A8 (en) 2002-05-23
AU3894700A (en) 2000-10-04
IL145240A (en) 2007-02-11
AU773188B2 (en) 2004-05-20
KR100432825B1 (ko) 2004-05-24
TR200102646T2 (tr) 2002-08-21
CA2367666A1 (en) 2000-09-21
SK12992001A3 (sk) 2002-03-05
NO20014479L (no) 2001-11-02
NZ514011A (en) 2001-09-28
ZA200107533B (en) 2002-12-12
AU773188C (en) 2006-01-05
PL351963A1 (en) 2003-07-14
HUP0200495A2 (en) 2002-08-28
ES2307501T3 (es) 2008-12-01
KR20020063107A (ko) 2002-08-01
BR0009026A (pt) 2003-03-05
MXPA01009404A (es) 2004-03-19
US6365633B1 (en) 2002-04-02
HK1045455B (zh) 2009-04-09
EP1178789B1 (en) 2008-07-16
CN1365276A (zh) 2002-08-21
HK1045455A1 (en) 2002-11-29

Similar Documents

Publication Publication Date Title
HUP0200495A3 (en) Method of treating eating disorders
GB2351661B (en) Novel method of treatment
GB9824436D0 (en) Methods of treatment
IL145875A0 (en) Novel method of treatment
GB9908175D0 (en) Method of treating neurological disorders
EP1207874A4 (en) METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES
HUP0200738A3 (en) Method of the treatment of incontinence
AU3757300A (en) Method of treating anxiety disorders
GB9930688D0 (en) Novel method of treatment
PL345261A1 (en) Method of treatment
PL349421A1 (en) Novel method of treatment
GB9930696D0 (en) Novel method of treatment
GB9822681D0 (en) Method of treatment
IL153788A0 (en) Treatment of eating disorders using carboxyalkylethers
GB9903950D0 (en) Method of treatment
GB9915597D0 (en) Method of treatment
TJ99000556A (en) Method of treatment of nevrodermite
GB9930689D0 (en) Novel method of treatment
GB0122638D0 (en) Novel method of treatment
GB9930692D0 (en) Novel method of treatment
GB9930690D0 (en) Novel method of treatment
EG24158A (en) Novel method of treatment
GB9811961D0 (en) Method of treatment
GB9818776D0 (en) Method of treatment
GB9808479D0 (en) Method of treatment

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees